Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Trends And Growth Drivers Point To Strong Future Potential
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The messenger ribonucleic acid (mrna) manufacturing service market size has experienced swift growth in recent years. It is anticipated to expand from $6.14 billion in 2025 to $7.12 billion in 2026, progressing at a compound annual growth rate (CAGR) of 15.9%. Historically, this growth can be attributed to the rise of mrna therapeutics research, vaccine emergency manufacturing demand, limited in house mrna capacity, growth of cdmo partnerships, and the expansion of biotech pipelines.
The messenger ribonucleic acid (mrna) manufacturing service market size is projected to experience significant expansion over the coming years. It is expected to grow to $12.97 billion in 2030, achieving a compound annual growth rate (CAGR) of 16.2%. This anticipated expansion during the forecast period is primarily driven by an increase in mrna therapy trials, the growing demand for contract manufacturing, the growth in personalized medicine, higher outsourcing by biotech firms, and the scaling up of commercial mrna products. Prominent trends identified for the upcoming period encompass integrated mrna process development services, large scale in vitro transcription production, end to end lnp encapsulation services, rapid technology transfer programs, and gmp grade mrna batch manufacturing.
Download A Free Sample Report For Comprehensive Market Insights:
Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Opportunity Drivers: What Is Creating New Revenue Potential?
The messenger ribonucleic acid (mRNA) manufacturing service market is anticipated to grow propelled by increasing clinical trial activity. This activity encompasses all processes involved in conducting and managing clinical studies to evaluate medical interventions in humans. Clinical trial activity is rising due to the growing adoption of digital and decentralized trial models, which facilitate faster patient recruitment, remote monitoring, and more efficient data collection across wider populations. Messenger ribonucleic acid (mRNA) manufacturing services support clinical trial activity by ensuring the rapid and flexible production of mRNA-based therapies, allowing for timely supply across multiple trial phases and accelerating drug development. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, reported that the number of industry clinical trials initiated in the UK rose to 426 in 2023, from 411 in 2022. Therefore, the escalating clinical trial activity is driving the expansion of the messenger ribonucleic acid (mRNA) manufacturing service market.
Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Segments: Where Are The Largest Growth Opportunities?
The messenger ribonucleic acid (mrna) manufacturing service market covered in this report is segmented –
1) By Service Type: Process Development; Analytical Testing; Manufacturing; Fill-Finish; Other Service Types
2) By Scale of Operation: Research And Preclinical Scale; Clinical Scale; Commercial Scale
3) By Application: Vaccines; Therapeutics; Research; Other Applications
4) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Other End-Users
Subsegments:
1) By Process Development: Template Design And Optimization; In Vitro Transcription Process Design; Formulation Development; Process Scale-Up And Technology Transfer; Process Validation Support
2) By Analytical Testing: Identity And Purity Testing; Potency And Functional Assays; Impurity And Contaminant Analysis; Stability And Shelf Life Studies; Quality Control Release Testing
3) By Manufacturing: Plasmid Deoxyribonucleic Acid Production; In Vitro Transcription Manufacturing; Enzymatic Capping And Tailoring; Purification And Concentration; Large-Scale Batch Production
4) By Fill-Finish: Aseptic Filling Services; Vial And Syringe Filling; Lyophilization Services; Labeling And Packaging; Cold Chain Handling And Storage
5) By Other Service Types: Regulatory Support Services; Quality Assurance And Documentation; Supply Chain And Logistics Support; Technology Consulting Services; Custom Manufacturing Solutions
Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Innovation Trends Driving Future Development
Key players within the messenger ribonucleic acid (mRNA) manufacturing service market are prioritizing the development of innovative solutions, such as in vitro transcription (IVT), to expedite the creation of high-quality, clinical-grade mRNA for vaccines and personalized therapies. In vitro transcription (IVT) describes a laboratory technique that synthesizes messenger RNA (mRNA) from a DNA template using RNA polymerase enzymes, enabling mRNA production outside living cells for research, therapeutic, or vaccine applications. For example, in May 2025, GenScript Biotech Corporation, a China-based biotechnology firm, introduced a GMP-like mRNA manufacturing service aimed at supporting preclinical studies and research essential for Investigational New Drug (IND) applications. This service offers high-purity, scalable in vitro transcription (IVT) processes with rigorous control over vital quality attributes like capping efficiency, poly(A) tail length, and impurity profiles. It facilitates a quick transition from preclinical to clinical stages by ensuring consistent production across batches, flexible customization for diverse mRNA constructs, and shortened development timelines. Moreover, the GMP-like framework ensures regulatory readiness through improved traceability, standardized operational procedures, and comprehensive quality documentation, helping developers reduce risks in subsequent manufacturing stages and accelerate clinical progress.
Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Major Participants And Competitive Dynamics
Major companies operating in the messenger ribonucleic acid (mrna) manufacturing service market are Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Biotechnologies, Evonik Industries AG, Lonza Group AG, Charles River Laboratories International Inc., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Recipharm AB, Curia Global Inc., Emergent BioSolutions Inc., AGC Biologics Inc., Corden Pharma International GmbH, Rentschler Biopharma SE, GenScript ProBio, ST Pharm Co. Ltd., etherna Immunotherapies NV, BIOMAY AG., Porton Advanced Solutions Ltd., Wacker Biotech GmbH.
Access The Complete Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Report:
Messenger Ribonucleic Acid (MRNA) Manufacturing Service Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the mRNA manufacturing service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) manufacturing service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
